Press Release
Stay updated with our latest news and media
FKUI Strengthens Stem Cell Research Collaboration: A Visit to Daewoong’s Production Facility
Writer
Manager
June 21, 2025

FKUI Strengthens Stem Cell Research Collaboration: A Visit to Daewoong’s Production Facility

 

The Faculty of Medicine atthe University of Indonesia (FKUI) persistently endeavors to fortify itscollaborative research in stem cell science with an array of global partners. As an extension of this commitment, a distinguished FKUI delegation, led by DeanProf. Dr. dr. Ari Fahrial Syam, SpPD-KGEH, MMB, conducted an official visit tothe Good Manufacturing Practice (GMP)-certified stem cell production facilityof Daewoong Biologics Indonesia in the Jababeka Industrial Estate, Cikarang,Bekasi, West Java, on Friday, February 7, 2025.

 

The visit aimed to deepen FKUI’s alliance with Daewoong in advancing and harnessing cutting-edge stem cell technologies for medical applications. During the excursion, thedelegation had the unique opportunity to meticulously scrutinize thesophisticated production processes powered by advanced South Korean technology.

 

Dean Prof. Ari Fahrial Syam remarked, “We profoundly appreciate Daewoong’s state-of-the-art facility forstem cell production. FKUI is resolutely committed to pioneering research andinnovative applications in stem cell science, and our strategic collaborationwith Daewoong is poised to catalyze transformative stem cell therapies forpatients across Indonesia.”

 

During the visit, Prof. Dr.dr. Lili Legiawati, Sp.D.V.E, Subsp.D.K.E, FINSDV, FAADV, a preeminent expertin Dermatology and Venereology at FKUI, accentuated the application ofsecretome—derivatives of stem cells—in dermatological treatments. Sheelaborated on its efficacy in addressing conditions such as androgeneticalopecia, skin aging, acne scarring, vitiligo, and other dermatologicaldisorders. “Empirical studies demonstrate that integrating conventionaltherapies with secretome not only augments patient outcomes but also redefinestreatment paradigms,” she explained.

 

Simultaneously, Dr. dr.Rahyussalim, Sp.OT(K)., Subsp.O.T.B, Manager of Research and Community Service at FKUI and an orthopedic clinician actively engaged in stem cell development,underscored the therapeutic merits of stem cell interventions in orthopedics.“Research on stem cell applications in orthopedics reveals markedly improvedoutcomes for spinal disorders—fortifying osteoporotic bones, rejuvenatingdegenerative discs even in advanced stages, and mitigating arthritic joint pain.These benefits extend to spinal nerves and musculature, even amongoctogenarians,” he asserted.

 

Dr. dr. Yetty Ramli, Sp.S(K) from the FKUI Department of Neurology, also elucidated the promisingpotential of stem cell therapies in neurology. “My investigations leverage stemcells to ameliorate adult conditions such as stroke, Parkinson’s disease,spinal cord injuries, cranial trauma, and peripheral nerve damage, whilepediatric applications address cerebral palsy, autism, and developmental disorders with superior efficacy compared to extant therapies,” she noted.

 

Since 2018, FKUI and Daewoong have nurtured a robust partnership in stem cell therapy, organoidresearch, gene editing, and biological investigations—initiatives thatcommenced with the establishment of the Biotechnology Research Center at UI andwere further advanced by inaugurating the UI Bioanalytical Center in 2022,dedicated to analyzing biological specimens critical for biopharmaceutical development. This collaboration has significantly propelled innovations in stem cell research, organoid engineering, and novel biological therapies.

 

“We anticipate that this strategiccollaboration will yield groundbreaking breakthroughs in stem cell-basedtherapies that not only revolutionize academic research but also delivertangible benefits to patients across Indonesia,” concluded Prof. Ari.

 

Baik In Hyun, Head of the Business Unit at Daewoong Biologics Indonesia, asserted, “Stem cell therapyholds immense promise to redefine patient care in Indonesia. Daewoong remainssteadfast in its commitment to sustaining strategic collaborations with preeminent academics and clinicians, including UI, to deliver superior qualitystem cell products that elevate healthcare standards nationwide.”

 

Accompanying the FKUIdelegation were notable figures including Prof. Dr. dr. Murti Andriastuti,Sp.A(K) (Manager of Education and Student Affairs for the Undergraduate,Medical Doctor, Master’s, and Doctoral Programs); Dr. dr. Rakhmad Hidayat,Sp.N., Subsp.NIIOO(K)., MARS (Director of Medical and Nursing Services atRSUI); Prof. Dr. dr. Ikhwan Rinaldi, Sp.PD-KHOM, M.Epid, M.Pd.Ked, FACP,FINASIM (Chair of the Department of Internal Medicine at FKUI); along withother esteemed FKUI staff such as Akhmad Noviandi Syarif, Sp.B.P.R.E.,Subsp.L.B.L (K); Dr. Farid Kurniawan, Sp.PD, Ph.D.; and the IMERI FKUI StemCell & Tissue Engineering Cluster team led by Dr. Radiana DhewayaniAntarianto, M.Biomed., Ph.D; Nuzli Fahdia M, M.Biomed; and Tri Kurniawati, SSi.

                                                                                                                                     -   # # # -

 

Ferry Maulana Prateja

Public Relations Supervisor

Daewoong Pharmaceutical Company Indonesia

+62 857 1839 7889

ferry.prateja@daewoong.co.kr

recent post
Forward
Indonesia News
Daewoong and Indonesia’s Ministry of Health Discuss Collaboration for Mutual Growth Aligned with Local Production of Medical Devices
Indonesia News
Daewoong Hadirkan Fexuprazan, Obat GERD Pilihan di 30 Negara, Siap Masuki Pasar Indonesia